Paper36912406
Can omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumab.
Ediger D and 3 others. Tuberk Toraks, 2023. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Can omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumab. Papers, record 36912406. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36912406
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Can omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumab.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Asthmatic Agents | Major topic |
| Asthma | Major topic |
| Adult | |
| Humans | |
| Omalizumab | |
| Retrospective Studies | |
| Antibodies, Monoclonal, Humanized | |
| Treatment Outcome | |
| Adrenal Cortex Hormones |
Source PubMed
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28859150 | The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study. | PLoS One | 2017 | https://conductscience.org/library/papers/28859150 | PubMed |
| 2 | 23350994 | Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. | J Asthma | 2013 | https://conductscience.org/library/papers/23350994 | PubMed |
| 3 | 8912771 | IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity. | Am J Respir Crit Care Med | 1996 | https://conductscience.org/library/papers/8912771 | PubMed |
| 4 | 19846286 | Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. | Respir Med | 2010 | https://conductscience.org/library/papers/19846286 | PubMed |
| 5 | 15733511 | Phenotypes of asthma revisited upon the presence of atopy. | Respir Med | 2005 | https://conductscience.org/library/papers/15733511 | PubMed |
| 6 | 28800272 | Omalizumab in non-allergic Asthma: A report of 13 cases. | J Asthma | 2018 | https://conductscience.org/library/papers/28800272 | PubMed |
| 7 | 26747278 | Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study. | BMC Pulm Med | 2016 | https://conductscience.org/library/papers/26747278 | PubMed |
| 8 | 33220106 | Real-life study in non-atopic severe asthma patients achieving disease control by omalizumab treatment. | Allergy | 2021 | https://conductscience.org/library/papers/33220106 | PubMed |
| 9 | 766679 | Immediate skin-test reactivity in a general population sample. | Ann Intern Med | 1976 | https://conductscience.org/library/papers/766679 | PubMed |
| 10 | 27824606 | Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. | Eur Respir J | 2016 | https://conductscience.org/library/papers/27824606 | PubMed |
| 11 | 29545284 | Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. | Eur Respir J | 2018 | https://conductscience.org/library/papers/29545284 | PubMed |
| 12 | 9689343 | Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and Phadiatop). Results from 8329 randomized adults from the SAPALDIA Study. Swiss Study on Air Pollution and Lung Diseases in Adults. | Allergy | 1998 | https://conductscience.org/library/papers/9689343 | PubMed |
| 13 | 22525394 | Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review. | Allergy Asthma Proc | 2012 | https://conductscience.org/library/papers/22525394 | PubMed |
| 14 | 30322442 | Omalizumab Treatment for Atopic Severe Persistant Asthma: A Single-Center, Long-Term, Real-Life Experience with 38 Patients. | Turk Thorac J | 2018 | https://conductscience.org/library/papers/30322442 | PubMed |
| 15 | 12100301 | Allergic vs nonallergic asthma: what makes the difference? | Allergy | 2002 | https://conductscience.org/library/papers/12100301 | PubMed |
| 16 | 27507234 | Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). | BMJ Open | 2016 | https://conductscience.org/library/papers/27507234 | PubMed |
| 17 | 23709757 | Against all odds: anti-IgE for intrinsic asthma? | Thorax | 2014 | https://conductscience.org/library/papers/23709757 | PubMed |
| 18 | 23579324 | A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. | Chest | 2013 | https://conductscience.org/library/papers/23579324 | PubMed |
| 19 | 21702660 | Asthma-related comorbidities. | Expert Rev Respir Med | 2011 | https://conductscience.org/library/papers/21702660 | PubMed |
| 20 | 28822787 | Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. | Lancet Respir Med | 2017 | https://conductscience.org/library/papers/28822787 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41790360 | Emerging Therapeutic Strategies in Asthma: Advances in Treatment, Drug Delivery, Drug Adherence, and Disease Management. | Curr Allergy Asthma Rep | 2026 | https://conductscience.org/library/papers/41790360 | PubMed |
| 40933990 | New insights into mesenchymal stem cells in inflammatory subtypes of asthma. | Front Immunol | 2025 | https://conductscience.org/library/papers/40933990 | PubMed |
| 40329860 | Obesity: Next game changer of allergic airway diseases? | Clin Transl Med | 2025 | https://conductscience.org/library/papers/40329860 | PubMed |
| 38878250 | Weighted Breaths: Exploring Biologic and Non-Biologic Therapies for Co-Existing Asthma and Obesity. | Curr Allergy Asthma Rep | 2024 | https://conductscience.org/library/papers/38878250 | PubMed |
| 38812719 | Pre-asthma: a useful concept? A EUFOREA paper. Part 2-late onset eosinophilic asthma. | Front Allergy | 2024 | https://conductscience.org/library/papers/38812719 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| IGHE | 3497 | PubTator's text mining | https://conductscience.org/library/genes/3497 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36912406
GET https://conductscience.org/api/papers/v1/36912406/references?page=2